Literature DB >> 26142205

Perturbations in fatty acid metabolism and apoptosis are manifested in calcific coronary artery disease: An exploratory lipidomic study.

Panagiotis A Vorkas1, Giorgis Isaac2, Anders Holmgren3, Elizabeth J Want1, John P Shockcor2, Elaine Holmes1, Michael Y Henein4.   

Abstract

BACKGROUND: Controversy exists concerning the beneficial or harmful effects of the presence of ectopic calcification in the coronary arteries. Additionally, further elucidation of the exact pathophysiological mechanism is needed. In this study, we sought to identify metabolic markers of vascular calcification that could assist in understanding the disease, monitoring its progress and generating hypotheses describing its pathophysiology.
METHODS: Untargeted lipid profiling and complementary modeling strategies were employed to compare serum samples from patients with different levels of calcific coronary artery disease (CCAD) based on their calcium score (CS). Subsequently, patients were divided into three groups: no calcification (NC; CS=0; n=26), mild calcification (MC; CS:1-250; n=27) and severe (SC; CS>250; n=17).
RESULTS: Phosphatidylcholine levels were found to be significantly altered in the disease states (p=0.001-0.04). Specifically, 18-carbon fatty acyl chain (FAC) phosphatidylcholines were detected in lower levels in the SC group, while 20:4 FAC lipid species were detected in higher concentrations. A statistical trend was observed with phosphatidylcholine lipids in the MC group, showing the same tendency as with the SC group. We also observed several sphingomyelin signals present at lower intensities in SC when compared with NC or MC groups (p=0.000001-0.01).
CONCLUSIONS: This is the first lipid profiling study reported in CCAD. Our data demonstrate dysregulations of phosphatidylcholine lipid species, which suggest perturbations in fatty acid elongation/desaturation. The altered levels of the 18-carbon and 20:4 FAC lipids may be indicative of disturbed inflammation homeostasis. The marked sphingomyelin dysregulation in SC is consistent with profound apoptosis as a potential mechanism of CCAD.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Calcification; Fatty acid; Lipidomics; Metabolomics; Metabonomics

Mesh:

Substances:

Year:  2015        PMID: 26142205     DOI: 10.1016/j.ijcard.2015.06.048

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  Lipidomic insight into cardiovascular diseases.

Authors:  Shohei Kohno; Audrey L Keenan; James M Ntambi; Makoto Miyazaki
Journal:  Biochem Biophys Res Commun       Date:  2018-04-19       Impact factor: 3.575

2.  Seminal plasma metabolomics and lipidomics profiling to identify signatures of pituitary stalk interruption syndrome.

Authors:  Ye Guo; Xiaogang Li; Xi Wang; Haolong Li; Guoju Luo; Yongzhen Si; Xueyan Wu; Yongzhe Li
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

Review 3.  Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies.

Authors:  Peter McGranaghan; Jennifer A Kirwan; Mariel A Garcia-Rivera; Burkert Pieske; Frank Edelmann; Florian Blaschke; Sandeep Appunni; Anshul Saxena; Muni Rubens; Emir Veledar; Tobias Daniel Trippel
Journal:  Metabolites       Date:  2021-09-14

Review 4.  Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges.

Authors:  Yin Tintut; Jeffrey J Hsu; Linda L Demer
Journal:  Front Cardiovasc Med       Date:  2018-11-23

5.  Serum untargeted lipidomic profiling reveals dysfunction of phospholipid metabolism in subclinical coronary artery disease.

Authors:  Demir Djekic; Rui Pinto; Dirk Repsilber; Tuulia Hyotylainen; Michael Henein
Journal:  Vasc Health Risk Manag       Date:  2019-05-13

6.  Differences in metabolic profiles between bicuspid and tricuspid aortic stenosis in the setting of transcatheter aortic valve replacement.

Authors:  Tian-Yuan Xiong; Chang Liu; Yan-Biao Liao; Wen Zheng; Yi-Jian Li; Xi Li; Yuanweixiang Ou; Zi-Jie Wang; Xi Wang; Chang-Ming Li; Zhen-Gang Zhao; Yuan Feng; Xiao-Jing Liu; Mao Chen
Journal:  BMC Cardiovasc Disord       Date:  2020-05-18       Impact factor: 2.298

7.  Seminal Plasma Lipidomics Profiling to Identify Signatures of Kallmann Syndrome.

Authors:  Xiaogang Li; Xi Wang; Haolong Li; Yongzhe Li; Ye Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-29       Impact factor: 5.555

8.  Metabolomic alterations associated with Behçet's disease.

Authors:  Wenjie Zheng; Xiuhua Wu; Maryam Goudarzi; Jing Shi; Wei Song; Chaoran Li; Jinjing Liu; Hua Chen; Xuan Zhang; Xiaofeng Zeng; Heng-Hong Li
Journal:  Arthritis Res Ther       Date:  2018-09-24       Impact factor: 5.156

9.  Identification of plasma lipid species as promising diagnostic markers for prostate cancer.

Authors:  Xiaoli Chen; Yong Zhu; Mayumi Jijiwa; Masaki Nasu; Junmei Ai; Shengming Dai; Bin Jiang; Jicai Zhang; Gang Huang; Youping Deng
Journal:  BMC Med Inform Decis Mak       Date:  2020-09-24       Impact factor: 2.796

10.  Metabolomic alterations associated with Kallmann syndrome.

Authors:  Ye Guo; Xiaogang Li; Songxin Yan; Yongzhe Li
Journal:  Ann Transl Med       Date:  2020-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.